laboratory specialized in the treatment of rare neurological diseases
  • [Corporate] Home Banner

About Theranexus

Theranexus is an innovative biopharmaceutical company that spun off from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in the treatment of rare central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells.

Theranexus has a unique advanced therapy candidate identification and characterization platform focused on rare neurological disorders and an initial drug candidate in clinical development for Batten disease.

Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).

Theranexus participates in several leading scientific conferences and business conventions

09/06/2022

Download PDF File(253Ko)

THERANEXUS publishes its 2021 full-year results and announces a shift of its strategic focus to rare neurological diseases

25/04/2022
Download PDF File (276Ko)

THERANEXUS unveils its scientific advances on the occasion of World Rare Disease Day 2022

24/02/2022
Download PDF File (544Ko)

THERANEXUS and BBDF start recruitment for phase I/II trial in Batten disease patients

03/02/2022
Download PDF File (373Ko)

THERANEXUS publishes its cash position as of 31 December 2021

13/01/2022
Download PDF File (355Ko)

October 6-7, 2022 : Investor Access, Paris